Repository logo
 

Vascular consequences of inflammation: a position statement from the ESH Working Group on Vascular Structure and Function and the ARTERY Society

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Type

Article

Change log

Authors

zanoli, luca 
briet, marie 
empana, jean phillippe 
Guimarães, Cunha Pedro 

Abstract

Inflammation is a physiological response to aggression of pathogenic agents aimed at eliminating the aggressor agent and promoting healing. Excessive inflammation, however, may contribute to tissue damage and an alteration of arterial structure and function. Increased arterial stiffness is a well-recognized cardiovascular risk factor independent of blood pressure levels and an intermediate endpoint for cardiovascular events. In the present review we discuss immune mediated mechanisms by which inflammation can influence arterial physiology and lead to vascular dysfunction such as atherosclerosis and arterial stiffening. We also show that acute inflammation predisposes the vasculature to arterial dysfunction and stiffening, and alteration of endothelial function and that chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease and psoriasis are accompanied by profound arterial dysfunction which is proportional to the severity of inflammation. Current findings suggest that treatment of inflammation by targeted drugs leads to regression of arterial dysfunction. There is hope that these treatments will improve outcomes for patients.

Description

Keywords

Arteries, Arthritis, Rheumatoid, Atherosclerosis, Heart Disease Risk Factors, Humans, Inflammation, Inflammatory Bowel Diseases, Vascular Diseases, Vascular Stiffness

Journal Title

Journal of Hypertension

Conference Name

Journal ISSN

0263-6352
1473-5598

Volume Title

38

Publisher

Wolters Kluwer Health

Rights

All rights reserved
Sponsorship
L.Z. was supported by 2016/2018 Department Research Plan of University of Catania, Department of Clinical and Experimental Medicine (Project #A). R.M.T. was supported by grants from the British Heart Foundation (CH/4/29762, RE/13/5/30177). The Antoine Caillon, Pierre Paradis and Ernesto L. Schiffrin work was supported by Canadian Institutes of Health Research (CIHR) grants 102606 and 123465, CIHR First Pilot Foundation Grant 143348, a Canada Research Chair (CRC) on Hypertension and Vascular Research by the CRC Government of Canada/CIHR Program, and by the Canada Fund for Innovation (all to ELS). B.S. was supported by grants from the Netherlands Organisation for Scientific Research (Rubicon 452172006) and from the European Union’s Horizon 2020 research and innovation program (no. 793805).